Is Mounjaro Safe for Pregnant Women?

The misconception worth correcting first: 'not enough data' does not mean probably fine

A question our prescribers hear regularly is whether Mounjaro could be taken in early pregnancy, on the basis that 'there's no proof it's harmful.' That framing gets the burden of proof the wrong way round for a prescription medicine taken by a developing foetus. The Mounjaro Summary Care Record on the electronic Medicines Compendium states clearly that tirzepatide is contraindicated in pregnancy, citing animal reproductive studies that showed adverse effects at doses relevant to the therapeutic range. In the absence of controlled human data (no clinical trials have been conducted in pregnant women, and none are likely to be) 'no proof of harm' and 'proven safe' are not the same thing.

This is not a Mounjaro-specific gap. It reflects how weight-loss medicines are developed and authorised. The NHS guidance on weight-management injections covers this directly, and the position has not changed since tirzepatide's UK authorisation: use in pregnancy is not recommended, full stop. If you are uncertain whether any statement you have read elsewhere meets that standard, it takes under a minute to check the patient information leaflet inside your pen's box, the pregnancy section is clearly headed and written in plain language.

What happens to tirzepatide's action during pregnancy

Mounjaro works across two gut-hormone pathways (GIP and GLP-1 receptors) that influence appetite, gastric emptying and blood-sugar regulation. Both receptor types are present in foetal tissues, and the broader GLP-1 receptor agonist class has been associated with reduced foetal growth in animal models. The NHS patient information for tirzepatide notes that it is not known whether the medicine affects an unborn child, and recommends telling your doctor immediately if you become pregnant or plan to become pregnant while taking it. Animal studies are not a perfect model for human pregnancy, but they are the only data available, and the signal they produced was sufficient for regulators to recommend avoidance. There is no trimester distinction in the guidance, it applies throughout, and if you want a full breakdown of whether Mounjaro is safe to take while pregnant, we cover the evidence in detail on that dedicated page. You can read more about how tirzepatide works and its broader effect profile on our Mounjaro overview page.

Weight gain during pregnancy is normal and expected. GLP-1 medicines are designed to reduce appetite and restrict intake, which is not a goal compatible with healthy foetal nutrition. That functional mismatch reinforces the clinical case, independent of any direct toxicity question.

Contraception, planning ahead, and what to do if you are already pregnant

UK guidance is specific about contraception while taking Mounjaro, and it is worth understanding the detail. Women using hormonal contraceptives (particularly oral pills) are advised to add a non-oral barrier method for the first four weeks of treatment and for four weeks after each dose increase. The reason is that Mounjaro slows gastric emptying, which can reduce how much of an oral pill is absorbed. A broader look at how Mounjaro affects women specifically covers this in more depth. The NHS England guidance on weight-management injections makes this point clearly.

If you are planning a pregnancy, the conversation with your prescriber should happen before you stop contraception, not after. There is currently no formally established washout period specified in the UK SmPC, so the timing of stopping treatment before conception is a clinical decision made with your doctor, based on your situation. Do not simply discontinue and assume the medicine has cleared; get individual advice. For more on the risks as they are understood, our page on Mounjaro and pregnancy risk covers the evidence in detail.

If you discover a pregnancy while taking Mounjaro, stop the medicine and contact your GP or midwife as soon as possible. There is no need to panic, but there is also no reason to continue while you wait for an appointment. A prescriber can review the situation, flag it to your maternity team, and advise on next steps. You can also contact our team directly through our support page; aftercare is available seven days a week.

After pregnancy and breastfeeding: when treatment can resume

Mounjaro is not recommended while breastfeeding. Animal studies show tirzepatide is present in milk, and if you want to understand whether Mounjaro is safe in pregnancy more broadly, including what the animal and human data do and do not tell us, that page brings together the current evidence in one place. The conservative guidance (which UK regulators apply when data are absent in a population where potential harm exists) is to avoid. If you are breastfeeding and thinking about restarting weight-loss treatment, that is a discussion for your GP or a prescriber once you have finished breastfeeding.

For women who have stopped Mounjaro during pregnancy and want to restart afterwards, the process is straightforward: a fresh clinical consultation, an updated prescriber review and, where applicable, re-titration from the appropriate starting point. The side-effect profile is the same on restart as it was at initiation, your body does not carry a tolerance from previous treatment. Our treatment consultation page is the starting point, and the clinical review happens the same day, conducted by a real prescriber, not an automated system. In the meantime, the treatment overview page gives a clear picture of the options available once you are in a position to consider them.